Rice Hall James & Associates
Rice Hall James & Associates reported 240 stocks worth $2.1B in its 13F filing for Q2 2026, filed Aug 7, 2026. Its largest holdings are LGND (4.2%), ACIW (2.5%) and ARLO (2.5%). Compared with Q1 2026, the fund opened new positions in ASND, OSK and PAR, added to ACIW, ARLO and ESTA, trimmed LGND, FN and DFIN and sold out of ASND, AMPH and VITL.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  LGND Ligand Pharmaceuticals Inc | $85.4M | 4.2% | 270K | −14K (−5%) | 8 of 8 | |
| 2 |  ACIW Aci Worldwide Inc | $50.6M | 2.5% | 1M | +3,239 (+0%) | 8 of 8 | |
| 3 |  ARLO Arlo Technologies Inc | $50.3M | 2.5% | 3.7M | +73K (+2%) | 8 of 8 | |
| 4 |  FN Fabrinet | $49.2M | 2.4% | 88K | −18K (−17%) | 8 of 8 | |
| 5 |  ESTA Establishment Labs Hldgs Inc | $48.1M | 2.3% | 561K | +12K (+2%) | 8 of 8 | |
| 6 |  XPO Xpo Inc | $46.2M | 2.3% | 225K | +579 (+0%) | 8 of 8 | |
| 7 |  ZD Ziff Davis Inc | $43M | 2.1% | 821K | +22K (+3%) | 8 of 8 | |
| 8 |  FOUR SHIFT4 Pmts Inc | $42.5M | 2.1% | 874K | +27K (+3%) | 8 of 8 | |
| 9 |  KNSA Kiniksa Pharmaceuticals Intl | $40M | 1.9% | 625K | +17K (+3%) | 8 of 8 | |
| 10 |  ASND Ascendis Pharma A/s | $39.6M | 1.9% | 149K | New position | 1 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
ASND Ascendis Pharma A/s | $33.9M | 148K |
AMICUS THERAPEUTICS INC | $11.1M | 771K |
SOLENO THERAPEUTICS INC | $6.9M | 206K |
 AMPH Amphastar Pharmaceuticals in | $3.7M | 187K |
 VITL Vital Farms Inc | $3.1M | 223K |
🔒 Free account: see all 17.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 7, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Rice Hall James & Associates 13F FAQ
What does Rice Hall James & Associates own?
Rice Hall James & Associates reported 240 stocks worth $2.1B in its 13F filing for Q2 2026, filed Aug 7, 2026. Its largest holdings are LGND (4.2%), ACIW (2.5%) and ARLO (2.5%). The table above lists every position in the filing (the top 10 without an account).
What did Rice Hall James & Associates buy and sell in Q2 2026?
Compared with Q1 2026: 14 new positions, 109 added to, 100 trimmed and 17 sold out. New positions include ASND, OSK and PAR. It sold all of ASND, AMPH and VITL.
When will Rice Hall James & Associates file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Rice Hall James & Associates's portfolio worth?
The Q2 2026 filing reports $2.1B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.